scholarly journals Prognostic Impact and Clinicopathological Features of Multiple Colorectal Cancers and Extracolorectal Malignancies: A Nationwide Retrospective Study

Digestion ◽  
2021 ◽  
pp. 1-10
Author(s):  
Kentaro Ochiai ◽  
Kazushige Kawai ◽  
Hiroaki Nozawa ◽  
Kazuhito Sasaki ◽  
Manabu Kaneko ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Clinicopathological Features ◽  
Stage I ◽  
Prognostic Impact ◽  
Poor Prognostic Factor ◽  
Lung Cancers ◽  
Multiple Primary Malignancies ◽  
Multiple Primary ◽  
Prostate Cancers ◽  
The Right

<b><i>Introduction:</i></b> Multiple primary malignancies (MPMs) are likely to develop in patients with colorectal cancer (CRC); however, their prognoses are unclear. This study aims to investigate the prognostic impacts and clinicopathological features of multiple CRCs and extracolorectal malignancies (EMs) with CRC. <b><i>Methods:</i></b> We retrospectively evaluated a total of 22,628 patients with stage I–III CRC who underwent curative resection at 24 referral institutes in Japan between January 2004 and December 2012. MPMs were classified as synchronous CRCs (SCRCs), metachronous CRCs, synchronous EMs (SEMs), and metachronous EMs. <b><i>Results:</i></b> The presence of SCRCs (odds ratio 1.54, <i>p</i> &#x3c; 0.001) was independently associated with SEMs in the multivariate analyses. SEMs were the strongest poor prognostic factor for OS (hazard ratio [HR] 2.21, <i>p</i> &#x3c; 0.001) and RFS (HR 1.69, <i>p</i> &#x3c; 0.001) compared with age, sex, and primary T and N factors. The incidence of stomach cancer was the highest in EMs, followed by lung, breast, and prostate cancers. Multiple CRCs were evenly distributed throughout the right-side colon to the rectum. <b><i>Discussion/Conclusion:</i></b> SEMs were a strong poor prognostic factor for patients with stage I–III CRC. Patients with CRC, particularly those with SCRCs, should be surveyed for SEMs, especially for stomach and lung cancers.

Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma?

2011 ◽  
Vol 120 (2) ◽  
pp. 189-192 ◽  
Author(s):  
Nicole D. Fleming ◽  
Scott E. Lentz ◽  
Ilana Cass ◽  
Andrew J. Li ◽  
Beth Y. Karlan ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Endometrial Adenocarcinoma ◽  
Older Age ◽  
Stage I ◽  
Poor Prognostic Factor

scholarly journals High-Tech radiotherapy for primary prostate cancers and synchronous other tumor in elderly

2021 ◽  
Vol 2 (3) ◽  
Author(s):  
Alessia Surgo ◽  
◽  
Ilaria Bonaparte ◽  
Fabiana Gregucci ◽  
Roberta Carbonara ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Seminal Vesicles ◽  
High Tech ◽  
Multiple Primary Malignancies ◽  
Primary Prostate Cancer ◽  
Multiple Primary ◽  
Synchronous Cancers ◽  
Prostate Cancers ◽  
Radio Chemotherapy

Aims: To report feasibility and efficacy of high-tech Radiotherapy (RT) for the treatment of synchronous Multiple Primary Malignancies (sMPM) for elderly patients with primary Prostate Cancer (PC). Methods: Two elderly patients with PC and synchronous Anal Cancer (AC) and sacrum chordoma, respectively, were described. The first one was treated with radical radio-chemotherapy. A total dose of 70 Gy / 65.5 Gy (28 fractions) was prescribed to prostate/ seminal vesicles, and concomitantly, 56 Gy / 50.4 Gy / 45 Gy were prescribed to tumor, anal canal/mesorectum/pelvic nodes, and inguinal nodes, respectively. For the second case, after resection of chordoma, adjuvant and prostate radical RT (65.5 Gy / 70 Gy) in 28 fractions were used. In both cases, Volumetric-Arc RT was performed. Results: Patients completed the planned treatment without severe toxicities. After a median follow-up of 12 months, no sign of PC and a controlled/reduction of chordoma/AC were observed. Conclusion: High-tech RT is safe and effective for sMPM elderly patients. Keywords: Synchronous cancers; Elderly; Treatment; Radiotherapy; Multidisciplinary evaluation.

Prognostic impact of chemoradiation-related lymphopenia in patients with gastric and gastroesophageal cancer.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 249-249
Author(s):  
Daniel W Kim ◽  
Grace Lee ◽  
Theodore S. Hong ◽  
Guichao Li ◽  
Eric Roeland ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cox Model ◽  
Gastroesophageal Junction ◽  
Concurrent Chemotherapy ◽  
Rank Test ◽  
Prognostic Impact ◽  
Poor Prognostic Factor ◽  
Risk Of Death ◽  
Increased Risk ◽  
Ecog Ps

249 Background: Limited data exists on how chemoradiation (CRT)-induced lymphopenia affects survival outcomes in patients with gastric and gastroesophageal junction (GEJ) cancer. We evaluated the association between severe lymphopenia and its association with survival in gastric and GEJ cancer patients treated with CRT. We hypothesized that severe lymphopenia would be a poor prognostic factor. Methods: We performed a retrospective analysis of 154 patients with stage 1-3 gastric or GEJ cancer who underwent CRT at our institution. Patients underwent photon-based radiation therapy (RT) with a median dose of 50.4 Gy (IQR 45.0-50.4 Gy) over 28 fractions and concurrent chemotherapy (CTX) with carboplatin/paclitaxel, 5-fluorouracil based regimen, or capecitabine. 49% received CTX prior to RT. 84% underwent surgical resection, 57% pre-CRT and 26% post-CRT. Absolute lymphocyte count (ALC) at baseline and at 2 months since initiating RT were analyzed. Severe lymphopenia, defined as Grade 3 or worse lymphopenia (ALC < 0.5 k/μl), was analyzed for any association with overall survival (OS). Results: Median time of follow up was 48 months. Median age was 65. 77% were male and 86% were Caucasian. ECOG PS was 0 or 1 in 90% and 2 in 10%. Tumor location was stomach in 38% and GEJ in 62%. Timing of CRT was preoperative among 68% and postoperative among 32%. The median ALC at baseline for the entire cohort was 1.6 k/ul (range 0.3-7.0 k/ul). At 2 months post-CRT, 49 (32%) patients had severe lymphopenia. Patients with severe lymphopenia post-CRT had a slightly lower baseline TLC compared to patients without severe lymphopenia (median TLC 1.4 k/ul vs. 1.6 k/ul; p = 0.005). There were no differences in disease and treatment characteristics between the two groups. On the multivariable Cox model, severe lymphopenia post-CRT was significantly associated with increased risk of death (HR = 3.99 [95% CI 1.55-10.28], p = 0.004). ECOG PS 2 (HR = 34.97 [95% CI 2.08-587.73], p = 0.014) and postoperative CRT (HR = 5.55 [95% CI 1.29-23.86], p = 0.021) also predicted worse OS. The 4-year OS among patients with severe lymphopenia was 41% vs. 61% among patients with vs. without severe lymphopenia (log-rank test p = 0.041). Conclusions: Severe lymphopenia significantly correlated with poorer OS in patients with gastric or GEJ cancer treated with CRT. CRT-induced lymphopenia may be an important prognostic factor for survival in this patient population. Closer observation in high-risk patients and treatment modifications may be potential approaches to mitigating CRT-induced lymphopenia.

Triple negative breast cancer: An institutional review

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22214-e22214
Author(s):  
M. Dioca ◽  
M. Savignano ◽  
L. Gimenez ◽  
L. Marino ◽  
C. Delfino ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Menopausal Status ◽  
Stage I ◽  
Poor Prognostic Factor ◽  
Risk Of Death ◽  
Increased Risk

e22214 Background: Triple negative breast cancer (BC) is a distinct group of tumors that show common but heterogeneous morphologic, genetic, and immunophenotypic features. Despite differences in the definition and prevalence, it comprises 8% to 20% of all breast cancers and is associated with an aggressive clinical course with significant risk of either local or systemic relapse and subsequent increased risk of death on short term follow up (particularly in the first 5 years).We study the pathological characteristics and the clinical outcome of a cohort of 77 triple negative BC patients (pts) diagnosed at our Institution. Methods: Between January 1999 and September 2008, 77 (stage I to III) triple negative BC pts. were retrospectively analyzed. All pts had their receptor status, Her neu, ck-5, ck-6 and staining for EGFR by the same pathologist. Pathological parameters (Pp) analyzed were: status of axilary lymph nodes (LN), nuclear grade, histologic grade, mitotic index and vascular invasion and the use of antraciclins in the adjuvant setting. Univariate and multivariate analysis (proporcional hazard regression Cox model) for the Pp associated with relapse, and the log rank test to compare two curves of each Pp for disease free survival (DFS), and overall survival (OS) were performed. Results: The median age was 57.8 years (range 30–86 years).The median follow up time was 57.7 months (range, 4- 241). From 77 Pts. analized, 65 (84.4%) were basal-like and 43 (64.6%) of those were GH3. Stage at the time of presentation was: 16 (20,7%) stage I; 40 (51,9%) stage II; 21 (27,7%) stage III. Pre-menopausal status was 29,48% (23 pts.), and 61% (47 pts) were LN negative. Overall, relapse rate was 38.5 % (n= 30), 63 Pts (81.8%) are still alive. Median DFS was not reached. Global DFS and OS were 59% and 79% respectively, and status of LN was the only prognostic factor. LN- vs LN+ DFS (p< 00.02) and OS p (< 0.02).All others Pp analyzed were not statistically significative. Conclusions: Despite previous studies have demonstrated that triple negative is an independent marker of poor prognosis in BC as a whole, in the LN-negative, and LN-positive groups, in this basal like population only positive LN was an independent poor prognostic factor for DFS and OS. No significant financial relationships to disclose.

Could the neutrophil to lymphocyte ratio be a poor prognostic factor for lung cancers?

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e19145-e19145
Author(s):  
Turgut Kacan ◽  
Nalan Babacan ◽  
Mehmet Metin Seker ◽  
Birsen Yucel ◽  
Aykut Bahceci ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Neutrophil To Lymphocyte Ratio ◽  
Poor Prognostic Factor ◽  
Lung Cancers ◽  
Lymphocyte Ratio

D2-40-positive lymphatic vessel invasion is not a poor prognostic factor in stage I lung adenocarcinoma

2013 ◽  
Vol 63 (4) ◽  
pp. 201-205 ◽  
Author(s):  
Kei Shimizu ◽  
Kazuhito Funai ◽  
Haruhiko Sugimura ◽  
Keigo Sekihara ◽  
Akikazu Kawase ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Lung Adenocarcinoma ◽  
Lymphatic Vessel ◽  
Lymphatic Vessel Invasion ◽  
Stage I ◽  
Poor Prognostic Factor ◽  
Vessel Invasion

scholarly journals Sarcopenia is a novel poor prognostic factor in male patients with pathological Stage I non-small cell lung cancer

2017 ◽  
Vol 47 (4) ◽  
pp. 363-368 ◽  
Author(s):  
Takuma Tsukioka ◽  
Noritoshi Nishiyama ◽  
Nobuhiro Izumi ◽  
Shinjiro Mizuguchi ◽  
Hiroaki Komatsu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage I ◽  
Pathological Stage ◽  
Small Cell Lung ◽  
Poor Prognostic Factor ◽  
Male Patients

Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarsinoma?

2010 ◽  
Vol 116 (3) ◽  
pp. 594
Author(s):  
N. Fleming ◽  
S. Lentz ◽  
S. Vasilev ◽  
M. Ellison ◽  
I. Cass ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Older Age ◽  
Stage I ◽  
Poor Prognostic Factor

scholarly journals The clinicopathological features and prognostic value of lymphovascular invasion in patients with upper tract urinary carcinoma after radical nephroureterectomy:  an updated systematic review and meta-analysis.

2019 ◽  
Author(s):  
Lijin Zhang ◽  
Bin Wu ◽  
Zhenlei Zha ◽  
Hu Zhao ◽  
Jun Yuan ◽  
...  
Keyword(s):  
Systematic Review ◽  
Prognostic Factor ◽  
Prognostic Value ◽  
Lymphovascular Invasion ◽  
Meta Analysis ◽  
Clinicopathological Features ◽  
Current Evidence ◽  
Radical Nephroureterectomy ◽  
Poor Prognostic Factor ◽  
Upper Tract

Abstract Background and Purpose: Although the prognostic value of lymphovascular invasion (LVI) for upper tract urinary carcinoma (UTUC) have been described. There is lack of consensus regarding the prognostic factor of LVI in UTUC. The aim of present study was to evaluate the current evidence regarding the contemporary role of LVI through systematic review and meta-analysis according to the updated literatures. Materials and Methods: In the light of Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines, a systematic search of Web of Science, PubMed and EMBASE was performed for all reports published until July 2019 that included detailed results on the predictors of LVI. Results: Our meta-analysis included thirty one eligible studies containing 14,653 UTUC patients (81-1,363 per study). According to our final results, there was a significant correlation of LVI with worse cancer-specific survival (CSS) (HR=1.62, 95 % CI: 1.49-1.76, p < 0.001), overall survival (OS) (HR=1.55, 95 % CI: 1.41-1.71, p < 0.001), recurrence-free survival (RFS) (HR=1.46, 95 % CI: 1.32-1.61, p < 0.001), cancer-specific mortality (CSM) (HR=1.25, 95 % CI: 1.00-1.56, p = 0.047) and recurrence(HR=1.23, 95 % CI: 1.03-1.48, p = 0.026). In addition, LVI was also correlated with advanced TNM stage (III/IV vs. I/II: OR = 7.63, 95% CI: 5.60–10.39, p < 0.001), higher tumor grade (3 vs. 1/2: OR = 5.61, 95% CI: 3.71–8.48, p < 0.001), lymph node metastasis (yes vs. no: OR = 4.95, 95% CI: 3.66–6.71, p < 0.001), carcinoma in situ (yes vs. no: OR = 1.92, 95% CI: 1.36–2.70, p < 0.001) and positive surgical margin (yes vs. no: OR = 4.38, 95% CI: 2.71–7.07, p < 0.001), but not related to gender (male vs. female: OR = 0.98, 95% CI: 0.80–1.19, p = 0.825) and multifocality (multifocal vs. unifocal: OR = 1.10, 95% CI: 0.82–1.47, p = 0.539). The funnel plot test indicated that no significant publication bias in the meta-analysis. Conclusions: This study demonstrated that LVI was associated with more aggressive clinicopathological features and could serve as a poor prognostic factor for patient with UTUC after radical nephroureterectomy.

Sign in / Sign up

Export Citation Format

Share Document